




PHARMACEUTICAL 2021

DYNAVAX TECHNOLOGIES CORP
Rank 286 of 402





RealRate

PHARMACEUTICAL 2021

DYNAVAX TECHNOLOGIES CORP Rank 286 of 402

DYNAVAX

The relative strengths and weaknesses of DYNAVAX TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DYNAVAX TECHNOLOGIES CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 30% points. The greatest weakness of DYNAVAX TECHNOLOGIES CORP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is 8.3%, being 39% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	290,015
Cost of Goods Sold	0
Intangible Assets	2,297
Liabilities, Current	77,411
Liabilities, Non-Current	217,168
Other Assets	30,393
Other Compr. Net Income	2,660
Other Expenses	21,997
Other Liabilities	0
Other Net Income	363
Other Revenues	54,257
Property and Equipment	30,567
Research and Development	28,607
Selling, General and Administrative Expense	79,256

Output Variable	Value in 1000 USD
Assets	353,272
Liabilities	294,579
Expenses	129,860
Revenues	54,257
Stockholders Equity	58,693
Net Income	-75,240
Comprehensive Net Income	-73,910
Economic Capital Ratio	8.3%